← Leaderboards
John V. Heymach
University Of Tx Md Anderson Can Ctr
$11,138,593
Attributed
$21,151,933
Total exposure
13
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5M · FY2011–25$5M$3.8M$2.5M$1.3M$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$32,063,810 · 14
By mechanism
R01$13,273,678 · 6
P50$12,647,369 · 5
U01$5,995,893 · 2
P30$146,870 · 1
Top collaborators
- Lauren Averett Byers10 shared
- Kwok Kin Wong9 shared
- John D Minna7 shared
- Bingliang Fang5 shared
- Philip Jones5 shared
- Julien Sage5 shared
- Jianjun Zhang5 shared
- Jack Roth2 shared
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Lauren Averett Byers$9,117,683
- George A. Calin$5,774,539
- Jianjun Zhang$2,808,388
- Johannes F Fahrmann$4,011,689
- Kathryn Ann Gold$1,170,673
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorResponsePre-ClinicalCancer PatientResistanceResearch PersonnelNon-Small-Cell Lung CarcinomaMouse ModelMultidisciplinaryPre-Clinical ModelClinical TrialsEpidermal Growth Factor ReceptorMalignant Neoplasm Of LungMutationMalignant NeoplasmsChemotherapyIn VivoImmunotherapyBaseNovel Therapeutic InterventionPublicationsInnovationRegimenTranslating
Grant awards (58)
Deciphering the structural determinants of response and resistance to HER2-targeted antibody-drug conjugates and tyrosine kinase inhibitors for HER2-mutant Non-Small Cell Lung Cancer$695,004
R01 · FY2025 · CA · contact PI
Molecular and immunological heterogeneity of Small Cell Lung Cancer (SCLC) and its impact on relapse and therapeutic response$605,520
U01 · FY2025 · CA
10 Lung Cancer$24,691
P30 · FY2025 · CA · contact PI
Targeting Lung Cancer Vulnerabilities$2,188,505
P50 · FY2024 · CA
Molecular and immunological heterogeneity of Small Cell Lung Cancer (SCLC) and its impact on relapse and therapeutic response$575,245
U01 · FY2024 · CA
Molecular features impacting drug resistance in atypical EGFR exon 18 and exon 20 mutant non-small cell lung cancers and the development of novel mutant-selective inhibitors$549,195
R01 · FY2024 · CA · contact PI
Therapeutic strategies against EGFR exon 20 mutant lung cancer$529,607
R01 · FY2024 · CA · contact PI
Project 2: Targeting Immune Vulnerabilities in Lung Cancer$309,392
P50 · FY2024 · CA · contact PI
DRP Core: Developmental Research Program$88,767
P50 · FY2024 · CA · contact PI
CEP Core: Career Enhancement Program$88,766
P50 · FY2024 · CA · contact PI
10 Lung Cancer$23,220
P30 · FY2024 · CA · contact PI
Targeting Lung Cancer Vulnerabilities$2,110,656
P50 · FY2023 · CA
Molecular features impacting drug resistance in atypical EGFR exon 18 and exon 20 mutant non-small cell lung cancers and the development of novel mutant-selective inhibitors$566,537
R01 · FY2023 · CA · contact PI
Molecular and immunological heterogeneity of Small Cell Lung Cancer (SCLC) and its impact on relapse and therapeutic response$561,956
U01 · FY2023 · CA
Therapeutic strategies against EGFR exon 20 mutant lung cancer$546,332
R01 · FY2023 · CA · contact PI
Project 2: Targeting Immune Vulnerabilities in Lung Cancer$322,336
P50 · FY2023 · CA · contact PI
Targeting Lung Cancer Vulnerabilities$118,034
P50 · FY2023 · CA
Targeting Lung Cancer Vulnerabilities$45,613
P50 · FY2023 · CA
10 Lung Cancer$18,707
P30 · FY2023 · CA · contact PI
Targeting Lung Cancer Vulnerabilities$2,120,114
P50 · FY2022 · CA
Molecular and immunological heterogeneity of Small Cell Lung Cancer (SCLC) and its impact on relapse and therapeutic response$593,411
U01 · FY2022 · CA
Molecular features impacting drug resistance in atypical EGFR exon 18 and exon 20 mutant non-small cell lung cancers and the development of novel mutant-selective inhibitors$566,537
R01 · FY2022 · CA · contact PI
Therapeutic strategies against EGFR exon 20 mutant lung cancer$546,332
R01 · FY2022 · CA · contact PI
Project 2: Targeting Immune Vulnerabilities in Lung Cancer$322,337
P50 · FY2022 · CA · contact PI
10 Lung Cancer$18,707
P30 · FY2022 · CA · contact PI
Targeting Lung Cancer Vulnerabilities$2,125,682
P50 · FY2021 · CA
Molecular and immunological heterogeneity of Small Cell Lung Cancer (SCLC) and its impact on relapse and therapeutic response$620,991
U01 · FY2021 · CA
Molecular features impacting drug resistance in atypical EGFR exon 18 and exon 20 mutant non-small cell lung cancers and the development of novel mutant-selective inhibitors$578,099
R01 · FY2021 · CA · contact PI
Therapeutic strategies against EGFR exon 20 mutant lung cancer$557,481
R01 · FY2021 · CA · contact PI
Novel therapeutic approaches for enhancing anti-tumor immunity in SCLC$551,067
U01 · FY2021 · CA · contact PI
Project 2: Targeting Immune Vulnerabilities in Lung Cancer$299,724
P50 · FY2021 · CA · contact PI
10 Lung Cancer$18,707
P30 · FY2021 · CA · contact PI
Targeting Lung Cancer Vulnerabilities$2,203,273
P50 · FY2020 · CA
Novel therapeutic approaches for enhancing anti-tumor immunity in SCLC$702,580
U01 · FY2020 · CA · contact PI
Therapeutic approaches for LKB1-deficient non-small cell lung cancer$605,252
R01 · FY2020 · CA · contact PI
Molecular features impacting drug resistance in atypical EGFR exon 18 and exon 20 mutant non-small cell lung cancers and the development of novel mutant-selective inhibitors$578,099
R01 · FY2020 · CA · contact PI
Therapeutic strategies against EGFR exon 20 mutant lung cancer$572,983
R01 · FY2020 · CA · contact PI
Project 2: Targeting Immune Vulnerabilities in Lung Cancer$304,170
P50 · FY2020 · CA · contact PI
10 Lung Cancer$18,676
P30 · FY2020 · CA · contact PI
Therapeutic approaches for LKB1-deficient non-small cell lung cancer$587,093
R01 · FY2019 · CA · contact PI
Novel therapeutic approaches for enhancing anti-tumor immunity in SCLC$573,659
U01 · FY2019 · CA · contact PI
Overcoming Resistance to Anti-EGFR Therapy by Drug Repurposing$498,667
R01 · FY2019 · CA
10 Lung Cancer$18,707
P30 · FY2019 · CA · contact PI
10 Lung Cancer$5,455
P30 · FY2019 · CA · contact PI
Therapeutic approaches for LKB1-deficient non-small cell lung cancer$605,252
R01 · FY2018 · CA · contact PI
Novel therapeutic approaches for enhancing anti-tumor immunity in SCLC$596,039
U01 · FY2018 · CA · contact PI
Overcoming Resistance to Anti-EGFR Therapy by Drug Repurposing$514,090
R01 · FY2018 · CA
Novel therapeutic approaches for enhancing anti-tumor immunity in SCLC$615,425
U01 · FY2017 · CA · contact PI
Therapeutic approaches for LKB1-deficient non-small cell lung cancer$605,252
R01 · FY2017 · CA · contact PI
Overcoming Resistance to Anti-EGFR Therapy by Drug Repurposing$514,090
R01 · FY2017 · CA
Therapeutic approaches for LKB1-deficient non-small cell lung cancer$620,252
R01 · FY2016 · CA · contact PI
Overcoming Resistance to Anti-EGFR Therapy by Drug Repurposing$514,090
R01 · FY2016 · CA
Overcoming Resistance to Anti-EGFR Therapy by Drug Repurposing$511,434
R01 · FY2015 · CA
Markers and therapeutic strategies for overcoming chemoradiotherapy resistance$286,702
R01 · FY2015 · CA · contact PI
Markers and therapeutic strategies for overcoming chemoradiotherapy resistance$277,158
R01 · FY2014 · CA · contact PI
Markers and therapeutic strategies for overcoming chemoradiotherapy resistance$267,571
R01 · FY2013 · CA · contact PI
Markers and therapeutic strategies for overcoming chemoradiotherapy resistance$290,070
R01 · FY2012 · CA · contact PI
Markers and therapeutic strategies for overcoming chemoradiotherapy resistance$290,499
R01 · FY2011 · CA · contact PI